Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

Oslo, Norway, October 10, 2025 - Primary insider Michael Engsig, Chief Executive Officer of Nykode Therapeutics ASA, has today acquired 55,944 shares in Nykode Therapeutics ASA at a price of NOK 1.79 per share. Following the transaction, Michael Engsig holds 71,794 shares in Nykode Therapeutics ASA.

Please see further details in the attached document.